Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II stu...

por Garcia-Alfonso, P, Muñoz-Martin, A, Mendez-Ureña, M, Quiben-Pereira, R, Gonzalez-Flores, E, Perez-Manga, G
Publicado 2009

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

por García-Alfonso, P, Muñoz-Martin, A J, Alvarez-Suarez, S, Jerez-Gilarranz, Y, Riesco-Martinez, M, Khosravi, P, Martin, M
Publicado 2010

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

por Sastre, J., Argilés, G., Benavides, M., Feliú, J., García-Alfonso, P., García-Carbonero, R., Grávalos, C., Guillén-Ponce, C., Martínez-Villacampa, M., Pericay, C.
Publicado 2014

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

por Aranda, E., Aparicio, J., Alonso, V., Garcia-Albeniz, X., Garcia-Alfonso, P., Salazar, R., Valladares, M., Vera, R., Vieitez, J. M., Garcia-Carbonero, R.
Publicado 2015

Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of...

por García-Alfonso, P., García-Carbonero, R., García-Foncillas, J., Pérez-Segura, P., Salazar, R., Vera, R., Ramón y Cajal, S., Hernández-Losa, J., Landolfi, S., Musulén, E., Cuatrecasas, M., Navarro, S.
Publicado 2020

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

por González Astorga, B., Salvà Ballabrera, F., Aranda Aguilar, E., Élez Fernández, E., García-Alfonso, P., González Flores, E., Vera García, R., Fernández Montes, A., López Muñoz, A. M., Salud Salvia, A.
Publicado 2021

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast...

por Obermannová, R., Van Cutsem, E., Yoshino, T., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., Garcia Alfonso, P., Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P., Lonardi, S., Kim, T. W., Yang, L., Nasroulah, F., Tabernero, J.
Publicado 2016

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO tria...

por Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Publicado 2019

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric can...

por Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Publicado 2019

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes fro...

por Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.-T., Garcia-Alfonso, P., Belani, A., Zhang, X., Tabernero, J.
Publicado 2022

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who ar...

por García-Alfonso, P., Saiz-Rodríguez, M., Mondéjar, R., Salazar, J., Páez, D., Borobia, A. M., Safont, M. J., García-García, I., Colomer, R., García-González, X., Herrero, M. J., López-Fernández, L. A., Abad-Santos, F.
Publicado 2021

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumo...

por Carrato, A., Benavides, M., Massutí, B., Ferreiro-Monteagudo, R., García Alfonso, P., Falcó, E., Reboredo, M., Cano, T., Gallego, J., Viéitez, J. M., Layos, L., Salud, A., Polo, E., Dotor, E., Durán-Ogalla, G., Rodriguez-Garrote, M., Calvo, A., Grande, E., Aranda, E.
Publicado 2019

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

por Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.
Publicado 2022

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—...

por Yoshino, T, Portnoy, D C, Obermannová, R, Bodoky, G, Prausová, J, Garcia-Carbonero, R, Ciuleanu, T, García-Alfonso, P, Cohn, A L, Van Cutsem, E, Yamazaki, K, Lonardi, S, Muro, K, Kim, T W, Yamaguchi, K, Grothey, A, O’Connor, J, Taieb, J, Wijayawardana, S R, Hozak, R R, Nasroulah, F, Tabernero, J
Publicado 2019

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma...

por Sastre, J., García-Alfonso, P., Viéitez, J.M., Cano, M.T., Rivera, F., Reina-Zoilo, J.J., Salud-Salvia, A., Quintero, G., Robles-Díaz, L., Safont, M.J., La Casta, A., Gil, S., Polo, E., Asensio-Martínez, E., García-Paredes, B., López, R.L., Guillot, M., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E.
Publicado 2021

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

por Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Publicado 2019

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

por Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Publicado 2019